JP2016506939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506939A5 JP2016506939A5 JP2015555608A JP2015555608A JP2016506939A5 JP 2016506939 A5 JP2016506939 A5 JP 2016506939A5 JP 2015555608 A JP2015555608 A JP 2015555608A JP 2015555608 A JP2015555608 A JP 2015555608A JP 2016506939 A5 JP2016506939 A5 JP 2016506939A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- methyl
- phen
- phenylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 230000007135 neurotoxicity Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010012218 Delirium Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 206010059491 Intracranial haematoma Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000022077 chronic encephalitis Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- -1 methoxy-ethyl Chemical group 0.000 claims 66
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 208000012661 Dyskinesia Diseases 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 230000033001 locomotion Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 claims 1
- AFFPZJFLSDVZBV-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C(F)(F)F AFFPZJFLSDVZBV-UHFFFAOYSA-N 0.000 claims 1
- OJYLXZSHZGXVBZ-UHFFFAOYSA-N 2-anilino-3,3-difluoro-N-methyl-2-phenylpropanehydrazide Chemical compound FC(C(C(=O)N(N)C)(NC1=CC=CC=C1)C1=CC=CC=C1)F OJYLXZSHZGXVBZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000009017 Athetosis Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012225 Delirium tremens Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 206010071390 Resting tremor Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- VLFDIUYGPMHLQA-UHFFFAOYSA-N anilinomethanesulfonamide Chemical compound C1(=CC=CC=C1)NCS(=O)(=O)N VLFDIUYGPMHLQA-UHFFFAOYSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004799 bromophenyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 230000009206 glutamatergic signaling Effects 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims 1
- 125000001288 lysyl group Chemical group 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XGEGHDBEHXKFPX-NJFSPNSNSA-N methylurea Chemical compound [14CH3]NC(N)=O XGEGHDBEHXKFPX-NJFSPNSNSA-N 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000004963 pathophysiological condition Effects 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004344 phenylpropyl group Chemical group 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 230000001144 postural effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361760367P | 2013-02-04 | 2013-02-04 | |
| US61/760,367 | 2013-02-04 | ||
| PCT/EP2014/000169 WO2014117920A1 (en) | 2013-02-04 | 2014-01-23 | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506939A JP2016506939A (ja) | 2016-03-07 |
| JP2016506939A5 true JP2016506939A5 (enExample) | 2018-04-19 |
| JP6402115B2 JP6402115B2 (ja) | 2018-10-10 |
Family
ID=50000953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555608A Expired - Fee Related JP6402115B2 (ja) | 2013-02-04 | 2014-01-23 | 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9708321B2 (enExample) |
| EP (1) | EP2951179B1 (enExample) |
| JP (1) | JP6402115B2 (enExample) |
| CN (1) | CN104955826B (enExample) |
| AU (1) | AU2014211728B2 (enExample) |
| CA (1) | CA2899957A1 (enExample) |
| ES (1) | ES2796858T3 (enExample) |
| WO (1) | WO2014117920A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10022359B2 (en) | 2014-11-21 | 2018-07-17 | Esteve Pharmaceuticals, S.A. | 1,9-diazaspiro undecane compounds having multimodal activity against pain |
| EP3313836B1 (en) | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3395804B1 (en) | 2016-09-08 | 2020-05-13 | Gachon University of Industry-Academic Cooperation Foundation | Novel spiroquinone derivative compound, production method thereof, and pharmaceutical composition for preventing or treating neurological disorders which contains same as active ingredient |
| CA3102326A1 (en) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| CN111253397B (zh) * | 2018-11-30 | 2023-11-14 | 上海迪诺医药科技有限公司 | Mnk抑制剂 |
| ES3022307T3 (en) * | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| UY39377A (es) | 2020-08-14 | 2022-03-31 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714093A (en) | 1970-05-19 | 1973-01-30 | American Home Prod | Spiro [heterocycloalkyl-2'(1'h)-quinazoline]-4'(3'h)-ones |
| JPS4867287A (enExample) * | 1971-12-20 | 1973-09-13 | ||
| US5206240A (en) * | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| WO2004022554A1 (en) * | 2002-09-07 | 2004-03-18 | Celltech R & D Limited | Quinazolinone derivatives |
| DE10250708A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| EP1619193A4 (en) | 2003-04-18 | 2010-08-11 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
| EP2123652A1 (en) | 2007-02-20 | 2009-11-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US20100144756A1 (en) | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| EP2311840A1 (en) | 2009-10-13 | 2011-04-20 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| CA2751761A1 (en) * | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011047481A1 (en) | 2009-10-23 | 2011-04-28 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011100607A1 (en) * | 2010-02-11 | 2011-08-18 | Vanderbilt University | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| WO2011143444A2 (en) | 2010-05-14 | 2011-11-17 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
| ITMI20122221A1 (it) * | 2012-12-21 | 2014-06-22 | C4T S C A R L | Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende |
-
2014
- 2014-01-23 CN CN201480007416.4A patent/CN104955826B/zh not_active Expired - Fee Related
- 2014-01-23 ES ES14701145T patent/ES2796858T3/es active Active
- 2014-01-23 JP JP2015555608A patent/JP6402115B2/ja not_active Expired - Fee Related
- 2014-01-23 CA CA2899957A patent/CA2899957A1/en not_active Abandoned
- 2014-01-23 AU AU2014211728A patent/AU2014211728B2/en not_active Ceased
- 2014-01-23 EP EP14701145.6A patent/EP2951179B1/en active Active
- 2014-01-23 WO PCT/EP2014/000169 patent/WO2014117920A1/en not_active Ceased
- 2014-01-23 US US14/765,615 patent/US9708321B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531020A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| JP2018502891A5 (enExample) | ||
| JP2014528485A5 (enExample) | ||
| JP2014526549A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2013512926A5 (enExample) | ||
| JP2014515008A5 (enExample) | ||
| JP2017512794A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2021519263A5 (enExample) | ||
| JP2013544277A5 (enExample) | ||
| JP2018514544A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2016506387A5 (enExample) | ||
| JP2013502423A5 (enExample) | ||
| JP2016517878A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| JP2017530199A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2019525939A5 (enExample) |